两部门促进食品药品科技创新:重点支持中药创新药和传统中成药研发

2018-02-02 方碧陶 中国中医

1月30日,国家食品药品监管总局和科技部联合发布《关于加强和促进食品药品科技创新工作的指导意见》。将重点支持中药创新药、民族药、天然药物、传统中成药的研发及其临床评价和质量控制技术研究。

1月30日,国家食品药品监管总局和科技部联合发布《关于加强和促进食品药品科技创新工作的指导意见》。将重点支持中药创新药、民族药、天然药物、传统中成药的研发及其临床评价和质量控制技术研究。

《指导意见》强调,将优化科技创新布局,着力提升食品药品领域科技创新支撑能力,重点支持中药创新药、民族药、天然药物、传统中成药的研发及其临床评价和质量控制技术研究等。

《指导意见》指出,要加强食品药品创新领域社会资源优势集成,建立多部门、多学科联合创新网络。积极建设高水平科技创新基地,围绕食品安全和药物创新建设重点实验室与创新平台。建立健全有关对创新药品医疗器械的政策扶持,培育高水平创新人才队伍。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-08-29 日月
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-04 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-04 gj0737
  6. [GetPortalCommentsPageByObjectIdResponse(id=1675427, encodeId=c61016e5427c4, content=<a href='/topic/show?id=a0542111129' target=_blank style='color:#2F92EE;'>#两部门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21111, encryptionId=a0542111129, topicName=两部门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f827226538, createdName=日月, createdTime=Wed Aug 29 22:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797106, encodeId=dceb1e9710668, content=<a href='/topic/show?id=bc7d2243ef2' target=_blank style='color:#2F92EE;'>#中药创新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22437, encryptionId=bc7d2243ef2, topicName=中药创新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Oct 02 10:54:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285525, encodeId=1b671285525fe, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300115, encodeId=6c691300115f7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585123, encodeId=d3e81585123d0, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617639, encodeId=695d161e63959, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Feb 04 09:54:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]

相关资讯

第16届中药全球化联盟会议:王国强:要找到中药科技创新的关键思路

8月18日,第16届中药全球化联盟会议在广东省广州市召开。国家卫生计生委副主任、国家中医药管理局局长王国强在会上强调,加快创新成果转化,在预防保健、临床治疗和康复提升等各个健康环节上发挥中医药的独特效用。提高质量标准整体研究的水平,加速推动中医药走入国际市场。

中国医院协会发布2017年医院科技创新奖获奖名单

为鼓励广大医院管理工作者进行管理实践创新和理论创新,促进我国医院管理水平提高,更好地服务医院改革发展,经科技部国家科学技术奖励工作办公室国科奖字[2009]66号文批准,中国医院协会设立中国医院协会医院科技创新奖。根据《中国医院协会医院科技创新奖奖励办法》、《中国医院协会医院科技创新奖奖励办法实施细则》和《关于推荐2017年中国医院协会医院科技创新奖的通知》等文件的规定,截至2017年4月15

“十三五”卫生与健康科技创新规划出炉 提出12项重点任务

科技部、国家卫生计生委等6部门日前联合印发《“十三五”卫生与健康科技创新专项规划》,强化五年规划的实施,将为助推健康中国建设提供坚实的科技支撑。

五大科技创新正在改变医疗

如果有一天,你发现人的皮肤也可以合成,千万不要惊讶。近日,5 个石墨烯投资项目在中国科学院重庆绿色智能技术研究院举行了签约仪式,其中就包括石墨烯高分子复合人工皮肤—— — 重建病人的皮肤屏障。除了石墨烯之外,医疗机器人、AR 等在医疗中的应用,都备受关注,成为医疗科技圈儿的“网红”。当今,医学技术的发展在不断细分的基础上已经开始走向学科间的融合。技术创新不再是一个学科努力的过程,而是不同领域之间相互交叉融合的结果。

复合人工皮肤 石墨烯大放异彩

在人工皮肤的研究中,研究者利用石墨烯为原料,研制出可用于促进创面修复的石墨烯高分子复合型人工皮肤。

广东布局未来五年卫生计生九大任务

1月16日,2018年广东省卫生和计划生育工作会议在广州召开。广东省卫计委主任段宇飞在大会上作出报告。

北京市医管局医学科技创新英文风采大赛决赛举办

11月17日,由北京市医院管理局工会、科教处联合举办的2017年北京市医院管理局医学科技创新英文风采大赛决赛在中国插花艺术博物馆花博宴会中心正式举办。